GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models

Glucagon-like peptide 1 receptor (GLP-1R) agonists decrease body weight and improve glycemic control in obesity and diabetes. Patient compliance and maximal efficacy of GLP-1 therapeutics are limited by adverse side effects, including nausea and emesis. In three different species (i.e., mice, rats,...

Descripción completa

Detalles Bibliográficos
Autores principales: Borner, Tito, Geisler, Caroline E., Fortin, Samantha M., Cosgrove, Richard, Alsina-Fernandez, Jorge, Dogra, Mridula, Doebley, Sarah, Sanchez-Navarro, Marcos J., Leon, Rosa M., Gaisinsky, Jane, White, Arianna, Bamezai, Ankur, Ghidewon, Misgana Y., Grill, Harvey J., Crist, Richard C., Reiner, Benjamin C., Ai, Minrong, Samms, Ricardo J., De Jonghe, Bart C., Hayes, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Obesity Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564411/
https://www.ncbi.nlm.nih.gov/pubmed/34380697
http://dx.doi.org/10.2337/db21-0459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564411/
https://www.ncbi.nlm.nih.gov/pubmed/34380697
http://dx.doi.org/10.2337/db21-0459

Ejemplares similares